| Name | Title | Contact Details |
|---|
Empi, Inc is a medical device company focused on products used for pain management, orthopedic rehabilitation and physical therapy. The Company develops, manufactures, markets and distributes a diverse range of non-invasive medical devices and related
Velcera is a Yardley, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Dental Arts Group is a dental organization that provides quality dental care in New Jersey and Pennsylvania. Their services include preventative, cosmetic, restorative, and implant dentistry, as well as specialty services such as Periodontics, Endodont...
YO1 Center is a destination well-being place which enhances health, agility and longevity and brings your state of mind to bliss and happiness. Built at the erstwhile Kutsher`s Resort in lush green surroundings that have two large lakes, it gives guests the opportunity to naturally revitalize their mind and body by employing the Eastern practices brought all the way from India, namely Naturopathy (or Nature Cure), Ayurveda, Yoga and Meditation, Physical Therapy, Acupuncture, Diet and Nutrition. YO1 (or Yauvan) in Sanskrit means Youth. It is the golden period in every human being`s life between teenage and adulthood. It highlights the yogic behavior of every individual in all walks of life. YO1 represents the manifestation of Yoga to fulfill the human quest of attaining eternal youth, through a complete rejuvenation of mind, body and soul. YO1 is about You+1, the literal Sanskrit meaning of Yoga being the `divine union`.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."